Skip to main content
Erschienen in: neuropsychiatrie 4/2017

08.08.2017 | original article

Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval

verfasst von: Alexander Schmidt, Peter Fischer, Beate Wally, Joachim Scharfetter

Erschienen in: neuropsychiatrie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Summary

A group effect is generally assumed regarding the prolongation of the QT interval through butyrophenone antipsychotics like haloperidol. Consequently intravenous administration of benperidol is seen critically notwithstanding sparse evidence; thus benperidol and haloperidol were compared regarding their cardiac risk of prolonging the QT interval when administered intravenously for acute sedation of psychotic patients. The QT interval was measured by a 12-lead ECG. For the correction of QT values Bazett’s formula was used. The resulting QTc intervals of the benperidol and the haloperidol group were compared using Mann–Whitney U-test. Our data provide statistical evidence for benperidol being less prone to cause QTc prolongation than haloperidol (p = 0.049). The results of our study indicate a more favourable risk profile of benperidol compared to haloperidol regarding QTc prolongation when administered intravenously.
Literatur
1.
Zurück zum Zitat Fachinformation Haldol® Injektionslösung. Janssen-Cilag Pharma GmbH. 2013. Fachinformation Haldol® Injektionslösung. Janssen-Cilag Pharma GmbH. 2013.
3.
Zurück zum Zitat Mayer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous Haloperidol and Torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):8–16.CrossRef Mayer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous Haloperidol and Torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):8–16.CrossRef
4.
Zurück zum Zitat Scharfetter J, Fischer P. QTc Veränderungen bei intravenöser Akutsedierung mit Haloperidol, Prothipendyl und Lorazepam. Neuropsychiatrie. 2014;28:1–5.CrossRefPubMed Scharfetter J, Fischer P. QTc Veränderungen bei intravenöser Akutsedierung mit Haloperidol, Prothipendyl und Lorazepam. Neuropsychiatrie. 2014;28:1–5.CrossRefPubMed
5.
Zurück zum Zitat Fachinformation Glianimon® Injektionslösung. Destin GmbH. 2014. Fachinformation Glianimon® Injektionslösung. Destin GmbH. 2014.
6.
Zurück zum Zitat Messer T, Pajonk FG, Müller MJ. Pharmakotherapie von psychiatrischen Akut- und Notfallsituationen. Nervenarzt. 2015;86:1097–110.CrossRefPubMed Messer T, Pajonk FG, Müller MJ. Pharmakotherapie von psychiatrischen Akut- und Notfallsituationen. Nervenarzt. 2015;86:1097–110.CrossRefPubMed
7.
Zurück zum Zitat Anonym. Amisulpride/benperidol/olanzapine: QT Interval Prolongation: Case Report. React Wkly. 2014;1497:6. Anonym. Amisulpride/benperidol/olanzapine: QT Interval Prolongation: Case Report. React Wkly. 2014;1497:6.
8.
Zurück zum Zitat Silvestre J, Prous J. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find Exp Clin Pharmacol. 2007;7:457–65.CrossRef Silvestre J, Prous J. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find Exp Clin Pharmacol. 2007;7:457–65.CrossRef
9.
Zurück zum Zitat Bazett HC. An analysis of time relations of electrocardiograms. Heart. 1920;7:353–67. Bazett HC. An analysis of time relations of electrocardiograms. Heart. 1920;7:353–67.
10.
Zurück zum Zitat Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanism and clinical management. Ther Adv Drug Saf. 2012;3(5):241–53.CrossRefPubMedPubMedCentral Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanism and clinical management. Ther Adv Drug Saf. 2012;3(5):241–53.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat DeBruin ML, Pettersson M, Meyboom RHB, Hoes AW, Leufkens HGM. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005;26:590–7.CrossRef DeBruin ML, Pettersson M, Meyboom RHB, Hoes AW, Leufkens HGM. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005;26:590–7.CrossRef
12.
Zurück zum Zitat Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164(12):1293–7.CrossRefPubMed Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164(12):1293–7.CrossRefPubMed
13.
Zurück zum Zitat Duprey MS, Al-Qadheeb N, Roberts R, Skrobik Y, Schumaker G, Devlin JW. The use of low-dose IV haloperidol is not associated mith Qtc prolongation: post hoc analysis of a randomized, placebo-controlled trial. Intensive Care Med. 2016;42:1818–9.CrossRefPubMed Duprey MS, Al-Qadheeb N, Roberts R, Skrobik Y, Schumaker G, Devlin JW. The use of low-dose IV haloperidol is not associated mith Qtc prolongation: post hoc analysis of a randomized, placebo-controlled trial. Intensive Care Med. 2016;42:1818–9.CrossRefPubMed
14.
Zurück zum Zitat Gaffigan ME, Bruner DI, Wason C, Pritchard A, Frumkin K. A randomized controlled trial of intravenous Haloperidol vs. intravenous Metoclopramide for acute migraine therapy in the emergency department. J Emerg Med. 2015;49(3):326–34.CrossRefPubMed Gaffigan ME, Bruner DI, Wason C, Pritchard A, Frumkin K. A randomized controlled trial of intravenous Haloperidol vs. intravenous Metoclopramide for acute migraine therapy in the emergency department. J Emerg Med. 2015;49(3):326–34.CrossRefPubMed
15.
Zurück zum Zitat Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected Torsadogenic and Nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316:1098–106.CrossRefPubMed Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected Torsadogenic and Nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316:1098–106.CrossRefPubMed
16.
Zurück zum Zitat Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686–93.CrossRefPubMed Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686–93.CrossRefPubMed
17.
Zurück zum Zitat Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243–65.CrossRefPubMed Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243–65.CrossRefPubMed
18.
Zurück zum Zitat Leucht S. Therapie der Schizophrenie. München: Urban&Fischer; 2007. Leucht S. Therapie der Schizophrenie. München: Urban&Fischer; 2007.
Metadaten
Titel
Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval
verfasst von
Alexander Schmidt
Peter Fischer
Beate Wally
Joachim Scharfetter
Publikationsdatum
08.08.2017
Verlag
Springer Vienna
Erschienen in
neuropsychiatrie / Ausgabe 4/2017
Print ISSN: 0948-6259
Elektronische ISSN: 2194-1327
DOI
https://doi.org/10.1007/s40211-017-0230-5

Weitere Artikel der Ausgabe 4/2017

neuropsychiatrie 4/2017 Zur Ausgabe